An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Rheumatoid Arthritis and an Inadequate Response or Intolerance to One Anti-Tumor Necrosis Factor (Anti-TNF) Agent
- Registration Number
- NCT01641952
- Lead Sponsor
- Hoffmann-La Roche
- Brief Summary
This observational, prospective, multicenter study will evaluate the efficacy and safety of MabThera/Rituxan in participants with active rheumatoid arthritis and an inadequate response or intolerance to one anti-TNF therapy. Participants who receive MabThera/Rituxan according to the current standard and in line with the summary of product characteristics at a dose of 1000 milligram (mg) intravenously on Days 1 and 15 will be followed for 20 weeks.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 505
- Adult participants, >/= 18 years of age
- Participants with rheumatoid arthritis, eligible for treatment with MabThera/Rituxan in accordance with summary of product characteristics (SPC)
- Inadequate response to a single TNF inhibitor defined as change in disease activity score-28 erythrocyte sedimentation rate (DAS28-ESR) <1.2 or DAS28-ESR >3.5 at 5 months after first course of anti-TNF therapy
- Participants with a clinical and biological evaluation performed within 12 weeks prior to enrollment may be included
- More than one previous anti-TNF therapies
- Any other biological therapy apart from the one anti-TNF therapy
- Hypersensitivity to rituximab or any of the excipients or to murine proteins
- Active severe infections
- Participants in a severely immunocompromised state
- Severe heart failure [New York Heart Association (NYHA) Class IV] or severe, uncontrolled cardiac disease
- Women of childbearing potential not willing to use contraception
- Pregnant or breastfeeding women
- Participation in another trial
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Rituximab Rituximab Participants who had an inadequate response or intolerance to one anti- tumor necrosis factor (anti-TNF) agent received rituximab (Mabthera) at a dose determined by the investigator, guided by the recommendation in the Summary of Product Characteristics.
- Primary Outcome Measures
Name Time Method Change From Baseline in DAS28-ESR at Week 20 Baseline and Week 20 DAS28 was calculated from SJC and TJC using an assessment of 28 joints, the erythrocyte sedimentation rate (ESR) (milliliter per hour \[ml/hr\]), and Patient's Global Assessment (PGH) of disease activity \[measured on a 0 to 100 millimeter (mm) Visual Analogue Scale (VAS) where 0=no disease activity and 100=worst disease activity\]. DAS28 was calculated using the following formula: DAS28 = 0.56\*square root (sqrt) (TJC28) + 0.28\*sqrt(SJC28) + 0.70\*natural logarithm (ln) (ESR) + 0.014\*PGH of disease activity. Total score range: 0-10, with a higher score indicated more disease activity. DAS28 \<=3.2 implied low disease activity, DAS \>3.2 to 5.1 implied moderate disease activity and DAS \>5.1 implied high disease activity, and DAS28 \<2.6 = clinical remission.
Mean DAS28-ESR Score at Visit 4 (Week 20) Week 20 DAS28 was calculated from SJC and TJC using an assessment of 28 joints, the erythrocyte sedimentation rate (ESR) (milliliter per hour \[ml/hr\]), and Patient's Global Assessment (PGH) of disease activity (measured on a 0 to 100 mm Visual Analogue Scale \[VAS\] where 0=no disease activity and 100=worst disease activity). DAS28 was calculated using the following formula: DAS28 = 0.56\*square root (sqrt) (TJC28) + 0.28\*sqrt(SJC28) + 0.70\*natural logarithm (ln) (ESR) + 0.014\*PGH of disease activity. Total score range: 0-10, with a higher score indicated more disease activity. DAS28 \<=3.2 implied low disease activity, DAS \>3.2 to 5.1 implied moderate disease activity and DAS \>5.1 implied high disease activity, and DAS28 \<2.6 = clinical remission.
Percentage of Participants With EULAR Response Week 20 The DAS28 score is a measure of the participant's disease activity. It is based on the tender joint count (28 joints), swollen joint count (28 joints), patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\], and ESR. DAS28 total scores range from 0 to 10. DAS28 \<=3.2 indicates low disease activity, DAS28 \>3.2 to 5.1 indicates moderate to high disease activity. A negative CFB indicates improvement. The DAS28-based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of CFB and the level of disease activity reached. Good response: DAS28 \<=3.2 and a CFB \>1.2. Moderate response: DAS28 \<=3.2 and CFB \>0.6 to \<=1.2, DAS28 \>3.2 to \<=5.1 and CFB \>1.2 or \>0.6 to \<=1.2, DAS28 \>5.1 and CFB \>1.2. No response: DAS28 \<=3.2 and CFB \>=0.6, DAS28 \>3.2 to \<=5.1 and CFB \<=0.6, DAS28 \>5.1 and CFB \>0.6 to \<=1.2 or \<=0.6.
Number of Participants With Adverse Events (AE) Up to 39 months An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
Percentage of Participant With Good or Moderate Response According to European League Against Rheumatism (EULAR) Response Criteria Week 20 The DAS28 score is a measure of the participant's disease activity. It is based on the tender joint count (28 joints), swollen joint count (28 joints), patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\], and ESR. DAS28 total scores range from 0 to 10. DAS28 \<=3.2 indicates low disease activity, DAS28 \>3.2 to 5.1 indicates moderate to high disease activity. A negative change from Baseline indicates improvement. The DAS28-based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline (CFB) and the level of disease activity reached. Good response: DAS28 \<=3.2 and a CFB \>1.2. Moderate response: DAS28 \<=3.2 and CFB \>0.6 to \<=1.2, DAS28 \>3.2 to \<=5.1 and CFB \>1.2 or \>0.6 to \<=1.2, DAS28 \>5.1 and CFB \>1.2. No response: DAS28 \<=3.2 and CFB \>=0.6, DAS28 \>3.2 to \<=5.1 and CFB \<=0.6, DAS28 \>5.1 and CFB \>0.6 to \<=1.2 or \<=0.6.
Percentage of Participants With Change in DAS28-ESR of Greater Than or Equal (>=) 1.2 After First Course of Treatment Week 20 DAS28 was calculated from SJC and TJC using an assessment of 28 joints, the erythrocyte sedimentation rate (ESR) (milliliter per hour \[ml/hr\]), and Patient's Global Assessment (PGH) of disease activity (measured on a 0 to 100 mm Visual Analogue Scale \[VAS\] where 0=no disease activity and 100=worst disease activity). DAS28 was calculated using the following formula: DAS28 = 0.56\*square root (sqrt) (TJC28) + 0.28\*sqrt(SJC28) + 0.70\*natural logarithm (ln) (ESR) + 0.014\*PGH of disease activity. Total score range: 0-10, with a higher score indicated more disease activity. DAS28 \<=3.2 implied low disease activity, DAS \>3.2 to 5.1 implied moderate disease activity and DAS \>5.1 implied high disease activity, and DAS28 \<2.6 = clinical remission.
Percentage of Participants With EULAR Response in Subgroup of Participants Who Had Been Treated With Anti-TNF Previously Week 20 The DAS28 score is a measure of the participant's disease activity. It is based on the tender joint count (28 joints), swollen joint count (28 joints), patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\], and ESR. DAS28 total scores range from 0 to 10. DAS28 \<=3.2 indicates low disease activity, DAS28 \>3.2 to 5.1 indicates moderate to high disease activity. A negative CFB indicates improvement. The DAS28-based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of CFB and the level of disease activity reached. Good response: DAS28 \<=3.2 and a CFB \>1.2. Moderate response: DAS28 \<=3.2 and CFB \>0.6 to \<=1.2, DAS28 \>3.2 to \<=5.1 and CFB \>1.2 or \>0.6 to \<=1.2, DAS28 \>5.1 and CFB \>1.2. No response: DAS28 \<=3.2 and CFB \>=0.6, DAS28 \>3.2 to \<=5.1 and CFB \<=0.6, DAS28 \>5.1 and CFB \>0.6 to \<=1.2 or \<=0.6.
Percentage of Participants With Remission (DAS28 <2.6) and Low Disease Activity Following Each Treatment Course Week 20 DAS28 was calculated from SJC and TJC using an assessment of 28 joints, the erythrocyte sedimentation rate (ESR) (milliliter per hour \[ml/hr\]), and Patient's Global Assessment (PGH) of disease activity (measured on a 0 to 100 mm Visual Analogue Scale \[VAS\] where 0=no disease activity and 100=worst disease activity). DAS28 was calculated using the following formula: DAS28 = 0.56\*square root (sqrt) (TJC28) + 0.28\*sqrt(SJC28) + 0.70\*natural logarithm (ln) (ESR) + 0.014\*PGH of disease activity. Total score range: 0-10, with a higher score indicated more disease activity. DAS28 \<=3.2 implied low disease activity, DAS \>3.2 to 5.1 implied moderate disease activity and DAS \>5.1 implied high disease activity, and DAS28 \<2.6 = clinical remission.
Number of Participants With Remission (DAS28 <2.6) and Low Disease Activity Following Each Treatment Course for Subgroup of Participants Who Had Been Treated With Etanercept or Adalimumab or Infliximab Before Rituximab Week 20 The DAS28 score is a measure of the participant's disease activity. It is based on the tender joint count (28 joints), swollen joint count (28 joints), patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\], and ESR. DAS28 total scores range from 0 to 10. DAS28 \<=3.2 indicates low disease activity, DAS28 \>3.2 to 5.1 indicates moderate to high disease activity. A negative change from Baseline (CFB) indicates improvement. The DAS28-based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of CFB and the level of disease activity reached. Good response: DAS28 \<=3.2 and a CFB \>1.2. Moderate response: DAS28 \<=3.2 and CFB \>0.6 to \<=1.2, DAS28 \>3.2 to \<=5.1 and CFB \>1.2 or \>0.6 to \<=1.2, DAS28 \>5.1 and CFB \>1.2. No response: DAS28 \<=3.2 and CFB \>=0.6, DAS28 \>3.2 to \<=5.1 and CFB \<=0.6, DAS28 \>5.1 and CFB \>0.6 to \<=1.2 or \<=0.6.
- Secondary Outcome Measures
Name Time Method Health Assessment Questionnaire (HAQ) Score at Week 20 Baseline and Week 20 HAQ is a self-completed patient questionnaire specific for rheumatoid arthritis (RA). It consists of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip; common daily activities. Each domain has at least 2 component questions. There are 4 possible responses for each component 0=without any difficulty 1=with some difficulty 2=with much difficulty 3=unable to do. Calculate HAQ the patient must have a domain score for at least 6 of 8 domains. The HAQ is the sum of the scores, divided by the number of domains that have a score (in range 6-8) for a total possible score minimum/maximum 0 (best) to 3 (worst). A negative change from baseline indicated improvement.